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Abstract
Aims/hypothesis The DIRECT (Diabetes Research on Patient
Stratification) Study is part of a EuropeanUnion Framework 7
Innovative Medicines Initiative project, a joint undertaking
between four industry and 21 academic partners throughout
Europe. The Consortium aims to discover and validate bio-
markers that: (1) predict the rate of glycaemic deterioration
before and after type 2 diabetes onset; (2) predict the response
to diabetes therapies; and (3) help stratify type 2 diabetes into
clearly definable disease subclasses that can be treated more
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effectively than without stratification. This paper describes
two new prospective cohort studies conducted as part of
DIRECT.
Methods Prediabetic participants (target sample size
2,200–2,700) and patients with newly diagnosed type 2
diabetes (target sample size ~1,000) are undergoing detailed
metabolic phenotyping at baseline and 18 months and
36 months later. Abdominal, pancreatic and liver fat is
assessed using MRI. Insulin secretion and action are assessed
using frequently sampled OGTTs in non-diabetic participants,
and frequently sampled mixed-meal tolerance tests in patients
with type 2 diabetes. Biosamples include venous blood, fae-
ces, urine and nail clippings, which, among other biochemical
analyses, will be characterised at genetic, transcriptomic,
metabolomic, proteomic and metagenomic levels. Lifestyle
is assessed using high-resolution triaxial accelerometry, 24 h
diet record, and food habit questionnaires.
Conclusions/interpretation DIRECT will yield an unprece-
dented array of biomaterials and data. This resource, available
through managed access to scientists within and outside the
Consortium, will facilitate the development of new treatments
and therapeutic strategies for the prevention and management
of type 2 diabetes.
Keywords Epigenetic . Gene–environment interaction .
Genome . Glycaemic control . Lifestyle . Microbiome .
Prediabetes . Proteome . Transcriptome . Type 2 diabetes
Abbreviations
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fsOGTT Frequently sampled OGTT
IMI Innovative Medicines Initiative
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Introduction
Type 2 diabetes is a highly prevalent disease that is usually
preceded by four pathophysiological phases: (1) a gradually
accumulating resistance to the peripheral effects of insulin on
cellular glucose transportation; (2) a compensatory rise in
endogenous insulin secretion; (3) a progressive failure of beta
cell function; (4) a corresponding loss of glycaemic control
that eventually manifests as type 2 diabetes. The order of these
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phases can differ, with the primordial defect in certain high-
risk populations appearing to be at the level of the pancreatic
beta cell rather than in peripheral cells [1]. In patients with
type 2 diabetes, clinical interventions initially focus on
regaining glucose homeostasis through lifestyle-induced
weight loss and/or with pharmacotherapies designed to reduce
hepatic glucose production (e.g. metformin), enhance beta cell
function (e.g. sulfonylureas), reduce glycogen concentrations
(e.g. gliptins) or sensitise peripheral cells to the effects of
insulin (e.g. thiazolidinediones). Each therapy is designed to
directly or indirectly enhance the function of the remaining
beta cells and/or improve insulin action; however, beta cell
mass and function usually continue to decline after the therapy
is initiated and thereafter the therapy’s effectiveness lessens as
the time since diagnosis increases. Indeed, roughly 25% of
patients with type 2 diabetes require exogenous insulin within
6 years of diagnosis, and 42% within 10 years [2].
Although the diagnosis of type 2 diabetes is straightfor-
ward, determined primarily on the basis of elevated blood
glucose concentrations, it is a diagnosis of exclusion, such
that it is diagnosed when no other plausible cause is known.
Patients vary greatly in their clinical characteristics, treatment
requirements, rate of glycaemic deterioration, and susceptibil-
ity to diabetic complications. As we discover more about the
aetiology of diabetes, it is likely that this group with ‘type 2
diabetes’ will be reclassified into other subclasses of diabetes
with different pathophysiologies. If these pathophysiological
subclasses could be identified before or around the time of
diagnosis, this information might help facilitate targeted inter-
ventions, which in turn might lead to improved treatment
effectiveness, a reduction in unnecessary side effects, less
costly treatments, better patient adherence to treatments, and
improved quality of life. The identification of biomarkers that
aid therapeutic targeting in prediabetes (Study 1) or early-
onset type 2 diabetes (Study 2) is a major innovative objective
of the DIRECT (Diabetes Research on Patient Stratification)
Consortium. The term ‘prediabetic’ is used in our paper be-
cause the target population of Study 1 was identified using a
risk prediction algorithm that explicitly seeks to identify men
and womenwho are in the prediabetic blood glucose or HbA1c
ranges and who are at elevated risk of rapid glycaemic dete-
rioration (seeMethods). Therefore, whilst many persons with-
in the general population who are defined to have ‘prediabetic’
levels of blood glucose will regress to normal glycaemia, most
in the Study 1 population are, by selection, likely to go on to
develop diabetes. We use the term ‘prediabetes’ with this
assumption from hereon.
The DIRECT Consortium was formed under the banner of
the Innovative Medicines Initiative (IMI), a joint undertaking
between the European Union (EU), European academic insti-
tutions and pharmaceutical companies that forms part of the
Seventh Framework Programme (FP7). The overarching ob-
jectives of the DIRECTConsortium are to identify biomarkers
that address current bottlenecks in diabetes drug development
and to develop a stratified medicines approach to treatment of
type 2 diabetes with either existing or novel therapies. The
DIRECT Consortium seeks to address two key areas in which
improvements in diabetic medicine are required: (1) the rate at
which peoples’ glycaemic control deteriorates either from
prediabetes to type 2 diabetes or through type 2 diabetes with
increasing treatment requirements; (2) the extent to which
certain therapeutic interventions (either pharmacological or
surgical) result in improved glycaemic control.
This paper concerns two multicentre prospective cohort
studies within DIRECT, which address the area of glycaemic
deterioration. These studies focus on amassing information
and biomaterials that will be used to discover novel bio-
markers for glycaemic deterioration in people at high risk of
developing type 2 diabetes (Study 1) and in those who have
recently been diagnosed with the disease (Study 2) (see Fig. 1
and www.direct-diabetes.org/). This paper overviews the
design and rationale of these two studies, in addition to a
description of approaches for biomarker discovery focused
on existing cohort studies that are accessible to the
Consortium.
Methods
The glycaemic deterioration work package (WP2) of the
DIRECT Study comprises four sub-studies, two of which
involve the collection of new data. Study 1 concerns recruit-
ment and follow-up of about 2,200–2,700 people with predi-
abetes to study glycaemic deterioration before diabetes diag-
nosis. Deep phenotyping will be performed at baseline and
after 18 and 36 months. Study 2 will address glycaemic
deterioration in about 1,000 patients with new-onset type 2
diabetes. Deep phenotyping will be performed at baseline and
after 18 months. Additional work in WP2 of the DIRECT
Study, which will not be discussed in depth here, will make
use of data from pre-existing cohorts [3–12]. The protocol
timeline for the visits and tests for Study 1 and Study 2 are
shown in Fig. 2.
Ethical, regulatory and legal considerations
As the DIRECT Study clinical centres are located across
Europe, in the absence of a pan-European unifying body for
research ethics approval, partners in each of the countries
represented in the DIRECT Consortium navigated their local
research ethics processes separately. This was necessary to
ensure that the DIRECT protocols conformed with each
DIRECT centre’s ethical, regulatory and legal requirements.
As well as adhering to external EU, national and local gover-
nance structures, an internal governance structure was imple-
mented to support the participant consent form sections
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relating to privacy, data sharing and data security, which were
established in consultation with all DIRECT partners. A com-
mittee was established to develop policies relating to the
handling of samples and data. To ensure that participant
privacy and data security standards are maintained, while
not unnecessarily impeding the research process and ensuring
equity for all research partners, a Data Access Committee
made up of Consortium members was formed, which is
responsible for reviewing, approving and enabling access to
data by research partners.
Methods common to Study 1 and Study 2
Anthropometric and blood pressure
All measurement procedures are standardised across study
sites and performed by trained nurses or research assistants.
Height is measured using calibrated wall-mounted
stadiometers, weight using calibrated scales, and waist, hip,
thigh and calf circumferences using non-stretchable measur-
ing tapes. Blood pressure is measured using calibrated manual
(or automatic) sphygmomanometers with an appropriately
sized arm cuff; three seated measures are recorded in each
participant. Some centres also estimate body composition
using bioimpedance scales, although this is not a requirement
of the core protocol.
Blood omics
Fasting blood samples are taken in both studies for genomic,
epigenomic, transcriptomic, proteomic and metabolomic
assessments. These analyses are carried out to allow systems-
based investigations, which will be a major feature of the
DIRECT Study [13]. A variety of omics data will be generated
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Fig. 1 Overview of the
biomarker discovery strategy in
the two prospective studies of the
DIRECT consortium (Studies 1
and 2). Persons at high risk of
glycaemic deterioration before
(Study 1) or soon after (Study 2)
the onset of type 2 diabetes are
enrolled and followed for
between 18 and 36months. Those
whose glycaemic control
deteriorates least and most are
selected for biomarker discovery.
Discovered biomarkers are
subsequently fed back to improve
risk prediction models, which will
be validated in other
epidemiological studies and
clinical trials organised by the
DIRECT Consortium and its
partners
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with validated methods to be defined in subsequent studies
depending on the hypotheses being tested. The omics methods
used will hence be described in detail in subsequent papers.
Beta cell function and insulin sensitivity
Beta cell function and insulin sensitivity will be assessed
using validated modelling methods based on an OGTT or a
mixed-meal tolerance test (MMTT), as well as empirical
indices [14, 15].
Microbiome assessment
A faecal sample for DNA isolation and metagenome deep
sequencing is collected under standardised conditions. These
samples are immediately frozen at home and transported to the
clinical research centres in cooled packages. The samples are
subsequently stored at −80°C until DNA extraction. Bacterial
DNAwill be extracted following standardised consensus pro-
cedures and subjected to deep metagenomic next generation
sequencing, as previously described [16]. For each sample,
3 Gb clean sequence data are generated, and, on the basis of
bacterial gene annotation, principal component and cluster
analyses are performed. Taxonomic classification of known
species, metagenomic assessment of unknown species, and
functional-potential analyses are undertaken to identify
changes in the gut microbiota composition and function and
to correlate such signatures with a series of biochemical and
physiological variables of the host [16].
Urine sample
A fasting urine sample is taken and a pregnancy test is per-
formed in premenopausal female participants. A dipstick test
is also performed on all urine samples using Multistix 10
(Bayer, Leverkusen, Germany). Samples are aliquoted into
plain tubes and stored at −80°C.
MRI
Magnetic resonance images are acquired on approximately
every second participant in sequence, within age (5 years) and
sex (male and female) strata, to ensure an approximately even
distribution of scans of men and women and across the spec-
trum of age in both studies at five locations throughout north-
ern Europe. Local protocols were standardised across study
centres by an experienced radiographer to harmonise the scan
methodology as far as possible given that each centre has
different equipment. Scans are made at 1.5 and 3.0T field
strengths, depending on equipment, and using different man-
ufacturers’ scanner models: Siemens Trio 3T (University of
Dundee, UK), Philips Intera 1.5T (University of Exeter, UK),
Siemens Espree 1.5T (University of Newcastle, UK), Philips
Achieva 3T (Copenhagen University, Denmark) and Siemens
Avanto 1.5T (University of Eastern Finland, Finland and VU
University Medical Center, Amsterdam, the Netherlands).
Abdominal MRI All participants are scanned in the prone
position with arms extended above the head. T1-weighted
images are acquired from the diaphragm to acetabulum using
the maximum field of view during free breathing (slice thick-
ness of 10 mm, with a slice gap of 10 mm).
Pancreatic volume Imaging of the pancreas is achieved fol-
lowing additional survey scans while in suspended respira-
tion. A three-dimensional T1-weighted scan with fat suppres-
sion is placed over the pancreas to cover the entire organ. A
block of 50–80 slices with a thickness ranging from 1.2 to
2 mm is used depending on scanner limitations. Scans are
performed in a single breath-hold on expiration.
Multi-echo for pancreatic liver fat The pancreas is identified
and further axial images are performed during suspended
respiration, which are used to position a single slice multi-
echo sequence through the pancreas using a surface coil.
Typical variables include: repetition time, 1,500 ms; field of
view, 500; slice thickness, 10 mm. Echo times vary between 8
and 20 ms, depending on the scanner used, and are chosen to
represent in and out of phase, the shortest acquired at 1.15 ms
and the longest at 23 ms. An identical single slice is then
acquired through the liver in the axial plane. This method has
been appropriately validated previously [17].
Raw data are converted into an analysable format using
Image J (Image; National Institutes of Health, Bethesda, MD).
An automated pixel-by-pixel analysis is performed to obtain
colour-coded parametric maps of the entire pancreas and liver
using Matlab version 7.7 (Mathworks, Natick, MA, USA).
Relative proportions of fat and water within each organ are
then calculated.
Dietary assessment
For the assessment of diet and nutrition, a 24 h multi-pass
dietary record is used. Diet assessments in each participant are
made the day before the study visit. Twenty-four hour multi-
pass dietary records are open-ended, do not require a high
degree of literacy, and impose a relatively low level of burden
on the respondent. The method is well validated against the
gold standard for energy intake quantification (double-
labelled water) and has good reproducibility [18–20]. The
methods for the dietary record and the food habit question-
naire have been validated as part of the Euroaction Study [21].
The method is structured into three levels of dietary
questioning or ‘passes’. The first pass aims to document a
‘usual’ day’s meal. The second pass aims to give the respon-
dent the time to reflect and add to the foods recorded in the
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first pass. The third pass of the food record aims to obtain
information about portion size and method of preparation
using a food portion size atlas. Participants also complete a
food habit questionnaire to assess the overall quality of the
diet against healthy eating and diabetes guidelines, and as an
internal quality control check for the record. Toenail clippings
for the objective assessment of trace elements are also collect-
ed using stainless-steel clippers and are stored in paper enve-
lopes in a cool, dry environment.
Analysis of diet data will be undertaken using Dietplan-6, a
comprehensive food analysis program (version 6.70.43, 2013;
Forestfield Software, Horsham, UK). Because Studies 1 and 2
are pan-European, diet questionnaires were written in several
languages. Thus, each questionnaire is translated into English
by a native speaker of the respective non-English language.
Micro- and macro-nutrient content are calculated in a way that
preserves the meal structure. Each individual’s questionnaire
contains the contribution of each food’s nutritional content
related to the total intake in the meal structure. Under- and
over-reporting of energy intake will be assessed using
Goldberg’s equation [22, 23].
Physical activity, sedentary behaviour and sleep assessment
Habitual physical activity is assessed using a wrist-worn
triaxial accelerometer (ActiGraph GT3X+; Actigraph
LLC, Pensacola, FL, USA). The monitor is fitted to
the participant’s non-dominant wrist using an adjustable
strap (Actigraph LLC). The participant is requested to
wear the monitor continuously for 10 days to allow
habitual uninterrupted measures of both sleep and phys-
ical activity. The monitor is set to record at 30 Hz with
the manufacturer’s sleep mode disabled. Participants
selected for detailed assessments at the 18-month and
final 36-month study visit (in Study 1) will wear an
additional monitor on their dominant hip. The partici-
pants are instructed to remove the monitor only when
undertaking water-based activities (deeper than 1 m and
lasting longer than 30 min), or if the monitor causes
discomfort. Participants are given a prepaid, addressed,
padded envelope in which to deposit the monitor and
return it. A wide variety of methods can be used to
analyse the raw data to provide meaningful summary
variables. The analytical methods used will depend on
the specific research question and will be described in
detail in subsequent papers.
Additional questionnaires
Questionnaire data are also collected on quality of life (SF12),
dental health status, family history of diabetes and medication
history.
Central database
A relational database has been constructed to store all fore-
ground data collected in the DIRECT project. This includes a
user-friendly interface for creating participant profiles, data
entry from case report forms, importing processed laboratory
and measurement data, and for data query. All samples are
barcoded, linked to the participant’s study identification num-
ber, and registered in the database. A comprehensive sample
and data-tracking approach ensures that samples can be local-
ised to the specific placeholder in a rack at a specified storage
facility, which is an important infrastructural feature of the
project that will minimise data loss due to human error.
Additional functions for data interrogation, reporting errors
and anomalies, and repair processes are built into the database.
The database was constructed using mySQL (version 5.1.46).
The backend was built using Perl (version 5.12.1), and the
frontend was built using Javascript (version 1.8.5) and jQuery
(version 1.7.1).
Statistical power
There are many possible scenarios under which analyses will
be performed in DIRECT. The following is merely an exam-
ple to illustrate the statistical power for one such scenario for
prediabetic participants. Analysis will involve linear regres-
sion analysis where we model the ability of a given biomarker
to predict change in a continuous trait outcome. Power will
vary depending on a variety of factors. However, we can
calculate an example where we use a range of biomarker
frequencies to show power for detecting difference in change
in glucose concentrations (population mean ± SD,
5.8±0.6 mmol/l) during the study. Where a dichotomous
biomarker is present in 10% of the cohort, we will have
99.9%, 99.9% and 73.9% power (α 0.05) to detect changes
in fasting glucose of 0.5 mmol/l, 0.2 mmol/l and 0.1 mmol/l,
respectively. If the biomarker is more common and the other
assumptions outlined above remain the same, power exceeds
95% in all examples. The power calculations above assume a
single hypothesis test. In DIRECT, we are likely to undertake
many thousands of hypothesis tests; therefore, determining
true from false positive findings will rely on replication stud-
ies (in existing epidemiological cohorts linked to DIRECT)
and validation studies (in clinical trials that will be undertaken
in the second stage of the DIRECT project).
Prediabetic glycaemic deterioration (Study 1)
Study 1 rationale
The primary objective of Study 1 is to collect biosamples and
information that might yield novel, predictive biomarkers for
glycaemic deterioration in non-diabetic high-risk participants.
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Study 1 participant identification
Participants in Study 1 were recruited from existing prospec-
tive cohort studies in or around each of the following Euro-
pean cities: Malmö, Sweden (Malmö Diet and Cancer Study
[12]); Amsterdam, The Netherlands (Hoorn Study [3]);
Copenhagen, Denmark (Inter99 [10]); and Kuopio, Finland
(METSIM [24]). A clinically practicable screening tool
(DIRECT-DETECT) was used to identify at-risk participants
from existing cohort studies, who were then recruited into this
new prospective cohort study (Study 1). Inclusion and exclu-
sion criteria for Study 1 are outlined in Table 1.
Participants invited to attend the baseline visit are defined as
‘prediabetic’ based on HbA1c (5.7–6.4%, 40–48 mmol/mol).
Participants with HbA1c values at baseline ≥6.5%, or who are
known to have prevalent diabetes according to the ADA 2011
criteria [25], are excluded. Participants who are clinically
diagnosed with diabetes during the course of the study will
be allowed to remain in the study provided that their fasting
blood glucose levels do not exceed 10 mmol/l at a follow-up
visit. Treatments and medications for diabetes and other indi-
cations are recorded. Those participants who have started
antidiabetic medications are asked to stop taking them 24 h
before the 18- and 36-month follow-up examinations to
minimise their effects on the interpretation of drug-sensitive
biomarkers.
Like other diabetes screening tools, DIRECT-DETECT is
neither 100% specific nor sensitive; thus, we anticipate that,
although on average glycaemic control will decline in the
cohort, the extent to which this occurs will vary widely across
the cohort. Thus, participants in the top and bottom quantiles
(n=300 per quantile) of the distribution of glycaemic change
in Study 1 will be selected for deeper phenotyping, and
comparisons will be made to identify biomarkers that differ
substantially between the two groups, and hence might im-
prove the predictive accuracy of the DIRECT-DETECT risk
prediction algorithms (see Fig. 1).
Development of the DIRECT-DETECT prediction model The
prediction tool comprises two models. The focus of the first
model is to identify non-diabetic individuals who are at high
risk of rapid, short-term glycaemic deterioration, predicted by
questionnaire variables only. The focus of the second model is
to further predict glycaemic deterioration by adding a recent
HbA1c measure to the model. The DIRECT-DETECT tool is
an adapted version of the DETECT-2 algorithm [26]. To create
the tool, data from three existing prospective cohort studies
(Hoorn Study, Cooperative Health Research in the Region of
Augsburg [KORA S4/F4 Study] and Inter99 Study; cohort
characteristics are presented in Table 2 and published in detail
elsewhere [3, 4, 10]) were used to model the relationships
between selected variables determined at baseline (age, BMI,
waist circumference, use of antihypertensive medication,
smoking and parental diabetes) and change in HbA1c during
the following 4–8 years.
The prediction models were developed in men and women
separately using linear regression equations. The models were
evaluated for their calibrative and discriminative abilities
using calibration plots (to assess agreement between the pre-
dicted and observed values of HbA1c) and by selecting par-
ticipants with the highest 50% observed and predicted HbA1c
values within whom sensitivity, specificity, and positive and
negative predictive values were assessed respectively. The
prediction models were internally validated using
bootstrapping techniques. External validation of the model
was performed in the METSIM cohort.
Table 1 Inclusion and exclusion criteria for Study 1
Inclusion criteria
• No treatment with insulin-sensitising, glucose-lowering or other
antidiabetic drugs
• Fasting capillary blood glucose <10 mmol/l at baseline
• White European (self-report of parental ethnicity)
• Age ≥35 and <75 years
Exclusion criteria
• Diagnosed diabetes of any type, HbA1c ≥6.5% (48 mmol/mol) or
fasting plasma glucose ≥7.0 mmol/l or 2 h plasma glucose
>11.0 mmol/l previously
• For women, pregnancy, lactation or plans to conceivewithin the study
period
• Use of a pacemaker
• Any other significant medical reason for exclusion as determined by
the investigator
Table 2 Description of the characteristics of the studies used to develop the DIRECT-DETECT prediction model
Characteristic All studies (n=6,136) Hoorn (n=1,345) KORA S4/F4 (n=904) Inter99 (n=3,887)
Age (years) 52 (30–79) 60 (50–77) 64 (55–74) 46 (30–61)
Sex (% male) 49% 46% 51% 50%
HbA1c at follow-up (%) 5.66±0.44 5.47±0.62 5.64±0.41 5.73±0.34
HbA1c at follow-up (mmol/mol) 38.4±4.8 36.3±6.8 38.1±4.5 3.91±3.7
Follow-up duration (years) 6 (4–8) 6.5 (4–8) 7 (6.5–8) 5.5 (5–6.5)
Values are mean (range) or mean ± SD
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Study 1 screening examination
Using the DIRECT-DETECT tool, a total of around 10,000
high-risk participants have been identified from the existing
population-based prospective cohort studies at each study
centre. The participants are ranked according to the
DIRECT-DETECT model scores, and the highest-ranking
are invited to attend a screening examination. A detailed
description of the risk prediction model will be published
elsewhere. To ensure that only high-risk individuals are invit-
ed to the full study, updated information on the prediction
variables and information on inclusion/exclusion criteria are
obtained, and HbA1c is measured at the screening examina-
tion. In some centres, fasting and/or 2 h glucose concentra-
tions are also measured at this stage and used for the same
purpose as HbA1c. Participants who satisfy the inclusion/
exclusion criteria (see Table 1) and have been identified as
being at high risk of glycaemic deterioration from retrospec-
tive cohort data are invited to attend the baseline visit. Partic-
ipants with apparently normal glycaemia who are determined
to be at high risk on the basis of the DIRECT-DETECTsecond
model score are also invited to participate in the full study. The
intention is to enrol between 2,200 and 2,700 of the highest-
risk persons across all DIRECT Study centres.
Study 1 baseline examination
Examinations are carried out the morning after a 10 h over-
night fast. Study-specific written, informed consent is obtain-
ed in person. Anthropometrics and blood pressure are mea-
sured. A stool sample, toenail clippings and urine sample are
collected. The participant is fitted with an accelerometer (as
outlined above) for measurement of physical activity, seden-
tary behaviour and sleep. Data on quality of life (SF12) and
diet (as outlined above) are obtained by questionnaire. Ab-
dominal MRI scans (as outlined above) are conducted. All
current medication including over-the-counter and herbal
medication is documented.
Frequently sampled OGTT (fsOGTT) For the collection of
blood, a cannula is inserted into a forearm vein for sampling
at time points 0, 15, 30, 45, 60, 90 and 120 min during the
75 g fsOGTT. Blood samples for downstream blood omics
processing (as described above) are extracted and stored. A
standard finger-stick fasting capillary blood glucose sample
(with a HemoCue Glucose 201 or similar) is taken before
the fsOGTT, and those with corrected fasting venous glu-
cose >10 mmol/l (capillary glucose >11 mmol/l) are ex-
cluded from the study. To adjust for difference between
plasma glucose and capillary blood glucose, a correction
factor of ~1.11 is applied manually or automatically, as per
most commercially available capillary blood glucose
meters [27].
Study 1 measurements between core examinations
All participants are provided with a finger-stick blood sam-
pling kit for the collection of a blood spot (as described above)
for HbA1c assessment, a non-stretchable tape measure for the
assessment of waist circumference, and a data collection form
for recording waist circumference and body weight. Partici-
pants are asked to use the same weighing scales throughout
the study so that home measurements can be calibrated with
clinical measurements. Each measurement is obtained at
18-week intervals from the baseline visit to the follow-up visit
18 months later (a total of three intermediate measurements).
The participant is requested to return the blood spots and
questionnaires to the study centre by surface mail in a prepaid
envelope. Blood spot measures are processed according to a
validated protocol [28].
Study 1 follow-up examinations at 18 and 36 months
Similar to the baseline visit, anthropometric, diet and quality-
of-life data, blood pressure, stool samples, toenail clippings
and urine samples are collected. The participant is fitted again
with the accelerometer for measurement of physical activity,
sedentary behaviour and sleep. Fasting and fsOGTT blood
samples are obtained. At the 18-month follow-up visit, the
300 participants at each end of the glycaemic change distri-
bution (n=600) are selected from the full cohort (N=2,200–
2,700) for additional deep phenotyping. The cut-off points for
the tails in the rate of glycaemic deterioration are determined
using data from the sequential HbA1c data collected during the
18-month follow-up period. Because participants within the
tails of this distribution will be identified as study data is
accrued, and many of these will be identified before all of
the sequential HbA1c data are available, it will be necessary to
predict the distribution of glycaemic change using all of the
available data at that time. This dataset will be continuously
updated with additional HbA1c data, thereby maximising the
correct classification of participants included in the deep-
phenotyped subgroup of Study 1. These participants have a
further MRI scan. An additional hip-worn accelerometer is
also fitted to these individuals to further assess physical activ-
ity, sedentary behaviour and sleep.
New-onset diabetes glycaemic deterioration (Study 2)
Study 2 rationale
The primary objective of Study 2 is to collect biosamples and
information that might yield novel, predictive biomarkers for
glycaemic deterioration in people who have recently been
diagnosed with type 2 diabetes.
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Study 2 participant identification
Participants in Study 2 of DIRECT are recruited from or
nearby each of the following European cities: Malmö, Swe-
den; Amsterdam, the Netherlands; Copenhagen, Denmark;
Exeter, UK; Newcastle, UK; Dundee, UK. Potential partici-
pants are recruited through targeted searches of existing data-
bases and research registers combined with person-to-person
contact at educational clinics and through routine retinal
screening programmes. The target sample size is 1,000 par-
ticipants evenly distributed across the six European centres.
Inclusion and exclusion criteria for Study 2 are shown in
Table 3.
Study 2 screening examination
Participant eligibility is assessed, and written informed con-
sent is obtained in person. Additional information on diabetic
complications and other comorbidities, family history and
lifestyle factors such as alcohol and smoking status are ob-
tained. All current medications including over-the-counter and
herbal medication are documented. Current HbA1c and renal
function are checked with venepuncture and local laboratory
analysis.
Study 2 baseline examination
Examinations are performed in the morning after a 10 h
overnight fast. Participants remain on their usual non-
diabetes medications; metformin, if used, is stopped for
the 24 h preceding the study visit and restarted immedi-
ately after. As with Study 1 (described above),
anthropometric, diet and quality of life data, blood pres-
sure, stool samples, toenail clippings and urine samples
are collected. An intravenous cannula is inserted into a
forearm vein according to local protocols. Baseline blood
samples are immediately collected for analysis of GAD
and islet antigen-2 antibodies, glucagon-like peptide-1,
glucagon, insulin, C-peptide, metabolomics, proteomics,
HbA1c, DNA and RNA. The participant is also fitted with
an accelerometer for measurement of physical activity,
sedentary behaviour and sleep over 10 days.
MMTT In addition, fasting samples (MMTT time point 0 min)
for glucose, insulin and C-peptide analysis are collected. As
part of the MMTT, participants consume 250 ml Fortisip
liquid drink (18.4 g carbohydrate per 100 ml) over a period
of 2–5 min. Blood samples are collected every 30 min for 2 h
for subsequent glucose, insulin and C-peptide assays. A post-
prandial urine sample is also collected, analysed with a simple
dipstick and stored for later C-peptide analysis. As part of the
baseline visit, all participants also have an abdominal MRI
scan, as described above.
Study 2 measurements between visits
Each participant’s diabetes management is continued as nor-
mal. For monitoring of beta cell function, participants collect
postprandial urine samples every 3 months, which are
returned to the study centre for analysis of C-peptide.
Study 2 follow-up examinations
Two follow-up study visits are carried out in Study 2, one at
9 months and another at 18months after the baseline visit. The
9-month follow-up involves a repeated medical assessment,
medication review and anthropometric assessment, as docu-
mented above for the baseline visit. Fasting blood samples are
collected in a manner identical with the baseline visit (exclud-
ing a blood sample for RNA processing and analysis). The
18-month follow-up examination is identical with the baseline
examination.
Summary
The IMI DIRECT Study is one of the largest and most
comprehensive projects ever undertaken for the discov-
ery and validation of biomarkers for glycaemic deterio-
ration and type 2 diabetes. WP2 of DIRECT focuses on
deriving new data and biomaterials from two new pro-
spective cohort studies, as well as assimilating data and
materials from existing cohort studies led by members
of the DIRECT Consortium. The new studies are
designed to: (1) identify persons who are clinically
Table 3 Study 2 inclusion and exclusion criteria
Inclusion criteria
• Patients diagnosed with type 2 diabetes not less than 6 months and
not more than 24 months before baseline examination
• Management by lifestyle with or without metformin therapy
• All HbA1c <7.6% (<60 mmol/mol) within previous 3 months
• White European
• Age ≥35 and <75
• Estimated GFR >50 ml/min
Exclusion criteria
• Type 1 diabetes
• A previous HbA1c >9.0% (>75 mmol/mol)
• Prior treatment with insulin or an oral hypoglycaemic agent other than
metformin
• BMI <20 or >50 kg/m2
• Pregnancy, lactation or plans to conceive within the study period
• Any other significant medical reason for exclusion as determined by
the investigator
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defined as being at high risk of rapid glycaemic deteri-
oration and, by consequence, type 2 diabetes, in whom
additional novel biomarkers that inform the prediction
of these outcomes can be discovered (Study 1); (2)
identify persons with recently diagnosed type 2 diabe-
tes, in whom novel biomarkers for diabetes progression
(glycaemic deterioration and failure of therapy) might
be found. These studies involve in-depth phenotyping
using a range of cutting-edge technologies such as: MRI
scans of the liver, pancreas and abdomen; metagenomics
of faecal DNA; genomic, epigenomic, transcriptomic,
proteomic and metabolomic assessments of blood and
urine; estimates of pancreatic insulin secretion and
insulin action; and detailed lifestyle assessments. The
hypotheses generated using these materials will be test-
ed in specially designed clinical trials, which take place
in the second part of the DIRECT Study.
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